In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Novartis Venture Funds leads Visiogen's $40mm Series E round

Executive Summary

Novartis Venture Funds has led the $40mm Series E financing for Visiogen (presbyopia- and cataract-correcting devices) and contributed a new board member. Technology Partners, another first-time investor, also contributed significantly and was joined by existing backers Three Arch Partners, New Leaf Venture Partners, Prospect Venture Partners, CMEA Ventures, and Foundation Medical Partners. The company will use the money to fund global commercialization of its accommodating intra-ocular lens Synchrony, which was recently launched in Europe and could be approved in the US next year. Including this round, Visiogen has raised over $80mm since it was founded in 2001.
Deal Industry
  • Medical Devices
  • Medical Devices
    • Implantable Devices
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies